Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$64.60M$64.60M+295.3% vs Q1 2017 Net Income-$35.36M-$35.36MN/M vs Q1 2017 EPS Diluted-$0.55-$0.55N/M vs Q1 2017 Operating Income-$30,739,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived-$47,834,000N/M Margins · derivedOperating margin-47.6%+192.6 pt vs Q1 2017
Net margin-54.7%
ended Mar 31, 2018 · filed May 3, 2018 · 33 d after period end